Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free PRM Stock Alerts

Proteome Sciences (PRM) Competitors

Proteome Sciences logo
GBX 1.53 +0.13 (+9.21%)
As of 09/11/2026 10:48 AM Eastern
Compare

PRM vs. YGEN, AGL, GENI, VRCI, and IDHC

Should you buy Proteome Sciences stock or one of its competitors? Proteome Sciences's main competitors and comparable companies include Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), Verici Dx (VRCI), and Integrated Diagnostics (IDHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Proteome Sciences compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, indicating that its stock price is 84% less volatile than the broader market.

Proteome Sciences has lower revenue, but higher earnings than Yourgene Health. Proteome Sciences is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
Proteome Sciences£3.76M1.43-£4.08M-£1.04N/A

Yourgene Health has a net margin of -27.55% compared to Proteome Sciences' net margin of -81.50%. Proteome Sciences' return on equity of 33.80% beat Yourgene Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
Proteome Sciences -81.50%33.80%-19.25%

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
Yourgene Health Neutral
Proteome Sciences Neutral

23.3% of Yourgene Health shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 64.4% of Yourgene Health shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Yourgene Health beats Proteome Sciences on 7 of the 10 factors compared between the two stocks.

How does Proteome Sciences compare to ANGLE?

Proteome Sciences (LON:PRM) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Proteome Sciences has a net margin of -81.50% compared to ANGLE's net margin of -1,444.04%. Proteome Sciences' return on equity of 33.80% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
ANGLE -1,444.04%-191.36%-29.89%

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
ANGLE Neutral

Proteome Sciences has higher revenue and earnings than ANGLE. Proteome Sciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.43-£4.08M-£1.04N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Proteome Sciences has a beta of 0.157, suggesting that its share price is 84% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

Summary

Proteome Sciences beats ANGLE on 7 of the 11 factors compared between the two stocks.

How does Proteome Sciences compare to GENinCode?

Proteome Sciences (LON:PRM) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
GENinCode Neutral

Proteome Sciences has higher revenue and earnings than GENinCode. Proteome Sciences is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.43-£4.08M-£1.04N/A
GENinCode£3.08M2.15-£6.10M-£2.08N/A

Proteome Sciences has a net margin of -81.50% compared to GENinCode's net margin of -185.47%. Proteome Sciences' return on equity of 33.80% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
GENinCode -185.47%-409.40%-63.99%

Proteome Sciences has a beta of 0.157, indicating that its share price is 84% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 11.4% of GENinCode shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 8.4% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Proteome Sciences beats GENinCode on 7 of the 11 factors compared between the two stocks.

How does Proteome Sciences compare to Verici Dx?

Verici Dx (LON:VRCI) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

15.9% of Verici Dx shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -193.05%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-193.05% -138.93% -26.14%
Proteome Sciences -81.50%33.80%-19.25%

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.66M1.25-£6.56M-£0.90N/A
Proteome Sciences£3.76M1.43-£4.08M-£1.04N/A

Verici Dx has a beta of 1.222, meaning that its share price is 22% more volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, meaning that its share price is 84% less volatile than the broader market.

In the previous week, Verici Dx had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Proteome Sciences. Proteome Sciences' average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Proteome Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Verici Dx Negative
Proteome Sciences Neutral

Summary

Proteome Sciences beats Verici Dx on 8 of the 13 factors compared between the two stocks.

How does Proteome Sciences compare to Integrated Diagnostics?

Proteome Sciences (LON:PRM) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Integrated Diagnostics had 1 more articles in the media than Proteome Sciences. MarketBeat recorded 1 mentions for Integrated Diagnostics and 0 mentions for Proteome Sciences. Proteome Sciences' average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Integrated Diagnostics Neutral

Integrated Diagnostics has a net margin of 16.49% compared to Proteome Sciences' net margin of -81.50%. Integrated Diagnostics' return on equity of 39.61% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Integrated Diagnostics 16.49%39.61%9.69%

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.43-£4.08M-£1.04N/A
Integrated Diagnostics£9.17B0.00£4.01T£250.030.00

Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.432, suggesting that its stock price is 57% less volatile than the broader market.

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by insiders. Comparatively, 78.4% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats Proteome Sciences on 11 of the 12 factors compared between the two stocks.

Get Proteome Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

PRM vs. The Competition

Export
MetricProteome SciencesLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£4.91M£9.74B£7.16B£2.51B
Dividend Yield6.17%1.48%2.57%6.25%
P/E Ratio-1.4766.42274.94366.83
Price / Sales1.43108.85686.5789,753.13
Price / Cash3.7326.3576.6527.89
Price / Book-0.865.2810.336.33
Net Income-£4.08M£56.67B£3.50B£5.89B
7 Day Performance-1.48%-2.15%-3.32%-0.69%
1 Month Performance-8.06%-1.93%-0.53%0.00%
1 Year Performance-54.49%25.04%23.51%19.96%

Proteome Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRM
Proteome Sciences
N/AGBX 1.53
+9.2%		N/A-54.5%£4.91M£3.76MN/A240
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-26.8%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.95
flat		N/A-40.2%£7.15M£3.08MN/A2,300
VRCI
Verici Dx
N/AGBX 0.20
-11.1%		N/A-60.0%£4.58M£3.66MN/A19

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:PRM) was last updated on 9/13/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel